Anuh Pharma Ltd

Anuh Pharma Ltd is currently experiencing extreme selling pressure, with the stock registering only sell orders and no buyers in the queue. This distress selling signals a challenging phase for the pharmaceutical and biotechnology company, as it continues to face a prolonged downtrend against broader market gains.

Anuh Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across various timeframes. Recent evaluation adjustments highlight a transition in the stock’s technical trend, prompting a closer examination of its price action and indicator readings amid broader market conditions.

Anuh Pharma has experienced a revision in its market evaluation following a complex interplay of financial performance, valuation metrics, and technical indicators. Despite recent quarterly setbacks and underperformance relative to broader indices, subtle shifts in technical trends and promoter activity have influenced the company’s overall market assessment.

Anuh Pharma, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators reveal a nuanced picture of the stock’s near-term trajectory, with mixed signals from key momentum and trend-following tools.

Anuh Pharma Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has declined significantly over various time frames, contrasting sharply with the Sensex's performance. Factors contributing to this trend include underperformance relative to its sector and trading below key moving averages.

Anuh Pharma, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment, indicating a shift in its technical outlook. The company has faced performance challenges, including a notable year-to-date decline, while promoter confidence appears to be rising with increased stakeholder holdings.

Anuh Pharma, a microcap in the Pharmaceuticals and Biotechnology sector, has experienced recent stock price fluctuations, currently at 81.49. The company shows bearish technical indicators and has underperformed the Sensex in the short term, though it has outperformed over the past three years, reflecting mixed market dynamics.

Anuh Pharma Ltd., a leading manufacturer of Active Pharmaceutical Ingredients (APIs) specialising in antibiotics and bulk drugs, finds itself navigating turbulent waters as its stock trades at ₹85.45, down 14.12% over the past year and significantly below its 52-week high of ₹121.00. With a market capitalisation of ₹856.00 crores, the micro-cap pharmaceutical company has delivered a mixed performance in FY2025, posting annual revenue of ₹661.00 crores—a modest 2.2% year-on-year growth—whilst net profit declined sharply to ₹47.00 crores from ₹60.00 crores in FY2024, representing a concerning 21.67% contraction.

Anuh Pharma has recently experienced a change in its evaluation, reflecting a shift in technical indicators. The company's financial performance shows mixed results, with a modest operating profit growth and a decline in profit after tax. However, it maintains a low debt-to-equity ratio and rising promoter confidence.

Anuh Pharma, a microcap in the Pharmaceuticals and Biotechnology sector, has seen notable stock price movements and significant volatility over the past year. Despite a recent strong weekly performance, its year-to-date results show a decline, contrasting with the broader market's gains, while long-term returns remain robust.